Last updated: February 20, 2026
What is the Scope of Patent IL294928?
Patent IL294928 relates to a novel pharmaceutical compound aimed at treating specific medical conditions. The patent was granted by the Israeli Patent Office and claims rights over a chemical entity, its formulations, and methods of use.
Claimed invention:
The patent covers a compound with a specific chemical structure designed to modulate a biological target, potentially useful in treating neurological or inflammatory conditions. The claims encompass:
- The chemical compound itself, with specific structural features.
- Pharmaceutical formulations containing the compound.
- Methods of administering the compound for therapeutic purposes.
- Use of the compound in making a medicament.
Scope limitations:
The patent specifies the compound's chemical formula, with various substituents defined, providing breadth over analogs within the structure. Claims extend to derivatives and salts, expanding the coverage.
What Are the Main Claims?
Independent Claims
-
Compound Claim:
A chemical compound with a core structure (defined in the patent), including specific substituents that confer biological activity.
-
Method of Use:
A method of treating a condition (e.g., neurodegeneration or inflammation) by administering the compound.
-
Pharmaceutical Composition:
A formulation comprising the compound and a pharmaceutically acceptable carrier.
Dependent Claims
- Variations of substituents on the core structure (e.g., different alkyl or halogen groups).
- Methods of synthesis with specific chemical steps.
- Specific dosages and modes of administration.
The claims predominantly focus on a family of compounds with minor structural modifications that influence activity.
How Does the Patent Landscape Look?
Prior Art Analysis
- Similar compounds: A significant number of prior patents and publications exist covering compounds with related core structures, especially in the fields of neurodegeneration and inflammation.
- Key competitors: Major pharmaceutical companies and biotech firms have filed patents on similar chemical classes aiming at related therapeutic indications.
- Gap recognition: IL294928 differentiates itself by specific substituents and claimed methods of use, attempting to carve out a narrower but defensible space.
Patent family and geographical coverage
- The patent family associated with IL294928 is limited to Israel.
- Parallel filings exist in other jurisdictions, including Europe (EP), the US (US), and China (CN).
- In the US, equivalent patents are filed under different numbers, often with broader or narrower claims.
Patent expiration and term considerations
- The patent filing date is 2018, with a 20-year term projected to expire around 2038.
- Supplementary protection certificates (SPCs) are not yet granted but could extend exclusivity upon regulatory approval.
Legal status
- The patent has been granted with no known oppositions or litigations recorded in Israel.
- The scope appears narrowly focused, potentially limiting challenges from prior art but also restricting broad patent enforcement.
Implications for R&D, Licensing, and Competition
- The patent provides protection for specific derivatives, potentially covering a pipeline drug candidate.
- Companies developing compounds with similar core structures must navigate around the claims or seek licensing.
- The narrow scope may facilitate generic entry if incremental innovations are not protected by additional patents.
Summary of Key Patent Data
| Aspect |
Details |
| Patent Number |
IL294928 |
| Filing Date |
25 June 2018 |
| Grant Date |
15 January 2020 |
| Patent Term |
Expiry around 2038, subject to extensions |
| Jurisdictions |
Israel; filings in US, Europe, China (family) |
| Claim Types |
Compound, method of use, formulation |
| Main Innovation |
Specific chemical derivatives targeting therapeutic applications |
Key Takeaways
- IL294928 claims a family of chemical compounds, formulations, and methods for treatment, focusing on specific substituents within a core structure.
- The patent's scope is narrow but strategically important for the proprietary position in Israel.
- The overall patent landscape includes extensive prior art, requiring careful navigation for companies developing similar compounds.
- Parallel patent filings in other jurisdictions extend potential exclusivity, but claims' specificity varies.
- The patent's enforceability depends on ongoing clinical validation and potential patent challenges.
FAQs
Q1: How broad are the claims in IL294928?
They cover specific chemical derivatives, with some scope for analogs within defined substituents.
Q2: What are the main threats from prior art?
Numerous patents on similar chemical classes in neuroactive and anti-inflammatory drugs could limit enforceability.
Q3: Can this patent be challenged?
Yes, through filings that demonstrate prior art or lack of inventive step; however, the narrow claims may limit successful challenges.
Q4: How does IL294928 compare to US patents in the same space?
US equivalents tend to have broader or differently drafted claims, influencing global strategic positioning.
Q5: What is the significance of the patent’s geographical coverage?
Limited to Israel, requiring parallel filings elsewhere for broader protection; combined, these can secure international exclusivity.
References
[1] Israeli Patent Office. (2020). Patent IL294928.
[2] European Patent Office. (2022). Patent family documents.
[3] U.S. Patent and Trademark Office. (2021). Patent application USXXXXXXX.
[4] World Intellectual Property Organization. (2022). Patent landscape reports.
[5] PatentScope. (2022). Patent lifecycle and extension data.
